$100,000.00 in Sales Expected for Geron Co. (NASDAQ:GERN) This Quarter

Brokerages expect that Geron Co. (NASDAQ:GERN – Get Rating) will announce sales of $100,000.00 for the current quarter, Zacks reports. Two analysts have issued estimates for Geron’s earnings. Geron posted sales of $110,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 9.1%. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Geron will report full year sales of $410,000.00 for the current financial year, with estimates ranging from $400,000.00 to $420,000.00. For the next fiscal year, analysts expect that the business will report sales of $5.45 million, with estimates ranging from $500,000.00 to $10.40 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Geron.

Geron (NASDAQ:GERN – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Geron had a negative return on equity of 85.84% and a negative net margin of 8,584.92%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share.

Several analysts have weighed in on the company. StockNews.com assumed coverage on Geron in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research upgraded Geron from a “sell” rating to a “hold” rating and set a $1.50 price objective for the company in a research report on Wednesday, May 11th. B. Riley reiterated a “buy” rating on shares of Geron in a research report on Friday, March 11th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Geron in a research note on Friday, March 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $4.17.

Shares of GERN stock opened at $1.29 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.77 and a current ratio of 3.77. Geron has a fifty-two week low of $0.99 and a fifty-two week high of $2.23. The stock has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $1.29. The company has a market capitalization of $486.91 million, a P/E ratio of -3.58 and a beta of 0.99.

Several institutional investors and hedge funds have recently bought and sold shares of GERN. BioImpact Capital LLC purchased a new stake in Geron in the third quarter worth $7,854,000. Vanguard Group Inc. grew its stake in Geron by 12.4% in the first quarter. Vanguard Group Inc. now owns 17,336,930 shares of the biopharmaceutical company’s stock worth $23,579,000 after purchasing an additional 1,910,182 shares during the period. State Street Corp grew its stake in Geron by 13.4% in the first quarter. State Street Corp now owns 13,518,850 shares of the biopharmaceutical company’s stock worth $18,386,000 after purchasing an additional 1,593,868 shares during the period. Bank of America Corp DE grew its stake in Geron by 1,890.7% in the fourth quarter. Bank of America Corp DE now owns 1,220,929 shares of the biopharmaceutical company’s stock worth $1,489,000 after purchasing an additional 1,159,597 shares during the period. Finally, Millennium Management LLC grew its stake in Geron by 59.1% in the third quarter. Millennium Management LLC now owns 1,430,713 shares of the biopharmaceutical company’s stock worth $1,960,000 after purchasing an additional 531,552 shares during the period. 47.75% of the stock is currently owned by hedge funds and other institutional investors.

About Geron (Get Rating)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

See Also